Q1 Earnings Estimate for ABCL Issued By Leerink Partnrs

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of AbCellera Biologics in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0.16) per share for the quarter. The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.17) EPS.

Several other analysts have also weighed in on ABCL. KeyCorp lifted their price objective on shares of AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Stifel Nicolaus dropped their price target on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Finally, Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research report on Monday, March 3rd.

AbCellera Biologics Price Performance

Shares of NASDAQ ABCL traded up $0.04 during mid-day trading on Friday, hitting $2.56. 3,291,691 shares of the stock traded hands, compared to its average volume of 2,640,512. The firm has a 50 day simple moving average of $2.48 and a two-hundred day simple moving average of $2.77. The company has a market cap of $762.85 million, a PE ratio of -4.20 and a beta of 0.50. AbCellera Biologics has a twelve month low of $1.89 and a twelve month high of $4.34.

Institutional Trading of AbCellera Biologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABCL. DKM Wealth Management Inc. purchased a new stake in AbCellera Biologics during the 4th quarter worth approximately $29,000. Janney Montgomery Scott LLC acquired a new position in AbCellera Biologics during the first quarter worth about $29,000. AssuredPartners Investment Advisors LLC acquired a new stake in shares of AbCellera Biologics during the 1st quarter worth about $34,000. State of New Jersey Common Pension Fund D acquired a new position in AbCellera Biologics during the 4th quarter worth about $36,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of AbCellera Biologics during the fourth quarter worth approximately $40,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.